Trial Profile
A Phase IV Pilot Study on Optimizing the Treatment in HBeAg Positive CHB Patients With Response Guide Treatment (RGT) Method.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 26 May 2016 Primary endpoint has not been met. (Change of quantitative HBsAg from baseline to EOF), as per results published in the Journal of Hepatology.
- 26 May 2016 Results published in the Journal of Hepatology
- 31 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.